The factor that could determine future breast cancer treatment
- Date:
- December 27, 2012
- Source:
- Garvan Institute of Medical Research
- Summary:
- Australian scientists have shown how a 'transcription factor' causes breast cancer to develop an aggressive subtype that lacks sensitivity to oestrogen and does not respond to anti-oestrogen therapies such as Tamoxifen and aromatase inhibitors. Transcription factors are molecules that switch genes on or off. In this case, the transcription factor known as 'ELF5' inhibits sensitivity to oestrogen very early in the life of a breast cancer cell.
- Share:
Australian scientists have shown how a 'transcription factor' causes breast cancer to develop an aggressive subtype that lacks sensitivity to estrogen and does not respond to anti-estrogen therapies such as Tamoxifen and aromatase inhibitors.
Transcription factors are molecules that switch genes on or off. In this case, the transcription factor known as 'ELF5' inhibits sensitivity to estrogen very early in the life of a breast cancer cell.
In 2008, Associate Professor Chris Ormandy from Sydney's Garvan Institute of Medical Research showed that ELF5 was responsible for the development of the estrogen-receptor-negative cells in the breast during pregnancy that produce milk.
In the current study Ormandy, in collaboration with Drs Maria Kalyuga and David Gallego-Ortega, has shown that the same molecular decision occurs in breast cancer and that ELF5 has the ability to change an existing tumour to an estrogen-insensitive type.
The team has also described the genetic mechanisms by which ELF5 opposes the action of estrogen, and has shown that it is possible to alter the subtype of breast cancer by manipulating ELF5 levels. The findings are published in the online journal PLoS Biology.
"This work tells us that cancers which become refractory to anti-estrogen treatment often do so by elevating their levels of ELF5 and becoming functionally estrogen receptor negative," said Ormandy.
"This raises the therapeutic option of manipulating ELF5 levels to treat breast cancer."
"As ELF5 is intracellular, this could possibly be done with small molecule therapies that target protein-to-protein interactions, or with small inhibitory RNAs."
"There is also the possibility of testing ELF5 levels in tumours to predict response to treatment and therefore guide treatment decisions."
"Our key discovery here is that by simply manipulating one transcription factor we can change the subtype of breast cancer."
Story Source:
Materials provided by Garvan Institute of Medical Research. Note: Content may be edited for style and length.
Journal Reference:
- Maria Kalyuga, David Gallego-Ortega, Heather J. Lee, Daniel L. Roden, Mark J. Cowley, C. Elizabeth Caldon, Andrew Stone, Stephanie L. Allerdice, Fatima Valdes-Mora, Rosalind Launchbury, Aaron L. Statham, Nicola Armstrong, M. Chehani Alles, Adelaide Young, Andrea Egger, Wendy Au, Catherine L. Piggin, Cara J. Evans, Anita Ledger, Tilman Brummer, Samantha R. Oakes, Warren Kaplan, Julia M. W. Gee, Robert I. Nicholson, Robert L. Sutherland, Alexander Swarbrick, Matthew J. Naylor, Susan J. Clark, Jason S. Carroll, Christopher J. Ormandy. ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer. PLoS Biology, 2012; 10 (12): e1001461 DOI: 10.1371/journal.pbio.1001461
Cite This Page: